![]() |
|
|
Vol. 304, Issue 1, 310-318, January 2003
Departments of Neuroscience (A.K., J.S., S.O.Ö.) and Clinical Neuroscience (L.T.), Karolinska Institutet, Stockholm, Sweden
| |
Abstract |
|---|
|
|
|---|
The ability of the two opioid receptor-like receptor 1 (ORL1) agonists nociceptin (5 nmol i.c.v.) and synthetic (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one hydrochloride (Ro 64-6198; 0.1, 0.3, and 1.0 mg/kg i.p.) and the opioid antagonist naloxone (0.1, 1.0, and 10.0 mg/kg s.c.) to modify ethanol-induced conditioned place preference was examined in NMRI male mice. The ORL1 agonists were found to significantly reduce the acquisition, expression, and ethanol-induced reinstatement of conditioned place preference. Unlike the ORL1 agonists, naloxone at the doses relevant for opioid receptor blockade failed to significantly influence the acquisition of ethanol-induced conditioned place preference. However, naloxone at 1.0 but not 0.1 mg/kg s.c. potently blocked the expression of ethanol-induced conditioned place preference and significantly inhibited ethanol-induced reinstatement of the conditioned place preference after extinction. Separate experiments indicated that nociceptin and Ro 64-6198 are both devoid of reinforcing or aversive properties. Naloxone, however, at 1.0 and 10.0 mg/kg, produced conditioned place aversion, indicating motivational properties of its own. Both nociceptin and Ro 64-6198 reduced locomotor activity after acute administration. However, tolerance developed very quickly to this effect and already after three i.c.v. (or i.p.) injections, there was no significant reduction of locomotor activity. It is concluded that ORL1 agonists can modulate the acquisition, expression, and reinstatement of the conditioned reinforcing effects of ethanol with no reinforcing or aversive properties of their own. This property might be a potential advantage in the treatment of alcoholism compared with nonselective opioid antagonist naltrexone.
| |
Introduction |
|---|
|
|
|---|
Relapse
to alcohol use after periods of abstinence is a common feature of
alcoholism. Animal models have contributed to the identification of
factors that may underlie the motivational aspects of ethanol and that
contribute to relapse to ethanol taking. Drug-seeking behavior for
ethanol can be initiated or maintained not only by the primary,
reinforcing effects of the drugs themselves but also by secondary,
drug-associated stimuli (for review, see O'Brien, 1975
). The most
common experimental model used to study relapse to drug seeking has
been the reinstatement procedure. After training to make a response to
self-administer a drug and the subsequent extinction of the acquired
response, an acute noncontingent injection of test drug (or acute
stress) results in the reinstatement of responding (Carroll and Comer,
1996
). The conditioned place preference (CPP) procedure provides an
alternative experimental approach to examine mechanisms underlying
relapse. In this procedure a particular stimulus context or test
environment is paired with the effects of the drug, without the animal
having to learn to make an explicit response to obtain the drug. In the
test trial, the animal is allowed to freely move between the test
environment previously paired with the drug administration and the
nondrug environment. By its behavior the animal can show which
environment it prefers (for review, see Tzschentke, 1998
). Recently,
this learning paradigm was used to assess the relapse effect of a
"priming" injection of a drug (e.g., cocaine; Mueller and Stewart,
2000
). It was shown that a priming injection of the drug used to induce the conditioned place preference, given after extinction conditions, restored the salience or attractiveness of the environment previously paired with drug administration.
The neurochemical substrates for relapse to ethanol have been studied
at some length. There is now evidence for a role of the opioid systems
in the risk for relapse due to their ability to mediate alcohol-induced
euphoria. Naltrexone, a nonselective opioid antagonist, has a proven
potential as a therapeutic agent for alcoholism. Naltrexone and its
short-lasting analog naloxone display "antialcohol" properties in
several behavioral paradigms (for review, see Froehlich and Li, 1994
).
Recent studies have also focused attention to the brain nociceptin
system in relation to the rewarding effects of ethanol (Ciccocioppo et
al., 1999
, 2000
; Martin-Fardon et al., 2000
). Nociceptin, a 17-amino
acid neuropeptide, was found to be a natural ligand of the G
protein-coupled opioid receptor-like 1 receptor (ORL1) (Meunier et al.,
1995
; Reinscheid et al., 1995
). Despite the structural similarity with
dynorphin-A, nociceptin does not bind to opioid receptors and its
pharmacological effects are not sensitive to naloxone treatment (Jenck
et al., 2000
). In general, nociceptin has an inhibitory role on
synaptic transmission in the central nervous system and thereby
may reduce the responsiveness to external (e.g., stress) or
pharmacological (e.g., ethanol) stimuli (Calo et al., 2000
). The
peptide has also been reported to inhibit the activation of
antinociceptive neurons in the nucleus raphe magnus and periaqueductal
gray as well as hypothalamic
-endorphinergic neurons, projecting to
the ventral tegmental area and nucleus accumbens (Wagner et al., 1998
).
Nociceptin, injected i.c.v., was found to modify ethanol intake in rats
and to prevent the acquisition of ethanol-induced conditioned place
preference in rats (Ciccocioppo et al., 1999
). The peptide also had an
inhibitory effect on ethanol-seeking behavior in rats trained for
ethanol self-administration after exposure to foot shock (Ciccocioppo et al., 2000
), and it significantly reduced the effects of foot shock
stress on ethanol-seeking behavior (Martin-Fardon et al., 2000
). In
place conditioning experiments in rats, nociceptin did not affect place
preference, suggesting that it is devoid of "motivational" properties of its own (Devine et al., 1996a
; Ciccocioppo et al., 1999
).
Studies on the functional role of the nociceptin receptor (ORL1) have
been hampered by the lack of potent and selective ligands. Recently,
the nonpeptide compound
(1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one hydrochloride (mol.wt. 438.017) (Ro 64-6198), which penetrates well to
brain after i.p. administration, has been described (Jenck et al.,
2000
; Wichmann et al., 2000
). Ro 64-6198 was shown to be a full agonist
with an affinity to the ORL1 receptor close to that of nociceptin
itself (Jenck et al., 2000
).
The aim of the present work is to investigate the effect of nociceptin and Ro 64-6198 on the acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice and to compare their effects with those of naloxone (a nonselective opioid antagonist). In addition, the role of endogenous nociceptin for the effects of ethanol in the same experimental paradigm was studied in pronociceptin gene knockout mice.
| |
Materials and Methods |
|---|
|
|
|---|
Animals
Experiments with naloxone, nociceptin, and Ro 64-6198 were carried out in male NMRI mice (20-25 g; B&K Universal, AB, Sweden). Animals were kept under standard laboratory conditions with free access to food pellets (low-protein diet) and tap water. The animals were housed four to six per cage in a light-controlled room (12-h light/dark cycle, light on at 6:00 AM) at 21°C and 60% humidity. The experiments were approved by the Northern Stockholm Ethics Board of Animal Experimentation. All experiments were performed between 10:00 AM and 1:00 PM.
Nociceptin knockout mice were obtained from Dr. F. Jenck (Roche CNS
Research, Basel, Switzerland). Briefly, a null mutation was introduced
into the coding region of the OFQ peptide of the mouse ppOFQ gene by
homologous recombination in embryonic stem cells of 129/Ola mice
(Koster et al., 1999
). Two clones were selected in which the correct
disruption at one ppOFQ allele was confirmed and were injected into
blastocysts of C57BL/6J embryos. Two male chimeric mice transmitted the
mutated allele to their offspring and were mated with C57BL/6J female
mice. Mice heterozygous for the ppOFQ mutation seemed normal, healthy,
and fertile for at least 12 months on the mixed 129/Ola-C57BL/6J
genetic background. Heterozygous mice (±) were intercrossed and the
offspring were genotyped by Southern blot or polymerase chain reaction.
Animals have not been backcrossed into a pure genetic background but
+/+ and
/
littermates of the F2 or F3 generation with mixed 129-C57 background were cumulated in groups. Data comparing male
/
and male
+/+ mice are presented.
Surgery and Cannulation
The mice were anesthetized with a combination of Ketalar (50 mg/ml ketamine hydrochloride, 1:10, 0.2 ml s.c.; Parke Davis, Barcelona, Spain) and Hypnorm (10 mg/ml fluanisonum + 0.2 mg/ml fentanylum; 1:10, 0.2 ml i.p.; Janssen, Beerse, Belgium). The body
temperature was maintained at 37°C using a thermostat-regulated heat
pad (CMA/105; CMA/Microdialysis, Stockholm, Sweden). Permanent steel
guide cannulae with an outer diameter of 0.4 mm (Plastics One,
Roanoke, VA) were implanted into the right lateral ventricle using
coordinates based on the stereotaxic plates [AP (bregma),
2.5 mm; L,
3 mm; V, 4.25 mm; Franklin and Paxinos, 1997
). Cannulae were fixed to
the scull by dental carboxylic cement (Durelon ESPE; Sollentuna,
Sweden). The animals were allowed to recover for 2 to 3 days in the
colony room (2-3 mice/cage) before the start of the experiment.
Drugs
Naloxone HCl (EndoLab, Wilmington, PA) was dissolved in saline and injected s.c. in a 5-ml/kg volume. Nociceptin (1-17, peptide free base, mol.wt. 1809; Tocris, Bristol, UK) was dissolved in artificial CSF just before injection. Artificial mice CSF contained 7.20 g/l NaCl, 1.96 g/l NaHCO3, 0.18 g/l KCl, 0.068 g/l KH2PO4, 0.16 g/l CaCl2, 0.17 g/l MgCl2 · 6H2O, 0.07 g/l Na2SO4, and 1.0 g/l glucose. The pH of the solution was adjusted to 7.1 with 0.01 N NaOH and HCl. After i.c.v. injection, the needle remained in place for 3 to 5 s.
Ro 64-6198 was a gift of Dr. Juergen Wichmann (F. Hoffmann-La Roche, Pharma Preclinical Research, Basel, Switzerland). The drug was freshly dissolved in saline and was administered i.p. (5-ml/kg injection volume).
Ethanol solutions (ethanol 95%, density = 0.89) were prepared with tap water (v/v) to the required concentration and were administered intragastrically through a specially designed Teflon-coated needle (AgnTho's, Lidingo, Sweden) in a volume 0.2 ml/mouse.
Conditioned Place Preference
Apparatus. Place preference experiments were performed in plastic shuttle boxes divided by guillotine doors into two compartments of equal size (25 × 25 × 25 cm) with different degrees of illumination (30 and 110 lux) and color (black and white, respectively). Floor texture (solid) was equal in both compartments. The location of the animal in the box was monitored with a video camera-based computerized imaging system (Videomot; TSE GmbH, Homburg, Germany).
Experimental Design.
Each experiment consisted of a
preconditioning, conditioning, and postconditioning phase (Fig.
1). During the preconditioning phase mice
were placed in the center of the white compartment facing the opened
door between the compartments. This 10-min procedure was repeated
1 h later. Time spent in the white compartment during the second
preconditioning session was defined as the baseline level of
preference. The experimental conditions were chosen (see above) to
result in a balanced preference for both compartments during the
preconditioning test. In addition, on the basis of the results from
preconditioning test we excluded from the experiments mice with a
tendency for unbalanced preference (more than 60% of time in one of
the compartments). Although the criteria for exclusion were relatively
strict, most of the mice were found to fulfill them (60-80% depending
on the group).
|
Effects of Nociceptin/Ro 64-6198/Naloxone on the Acquisition of Ethanol-Induced Place Conditioning. The experiments were performed as described above but during the conditioning period mice were pretreated 2 min before the second conditioning trial (0.8 g/kg ethanol or water administration) with nociceptin (5 nmol in 2 µl/mouse i.c.v.) or Ro 64-6198 (0.3, 1.0, and 3.0 mg/kg i.p.) or naloxone (0.1, 1.0, and 10.0 mg/kg s.c.). Animals in the control group received i.c.v. injections of artificial cerebrospinal fluid (2 µl) or i.p./s.c. injection of saline, respectively.
Effects of Nociceptin/Ro 64-6198/Naloxone on the Expression of Ethanol-Induced Place Conditioning. The experiments were performed as described above (conditioning with 0.8-g/kg ethanol dose). Nociceptin (5 nmol/2 µl i.c.v.) or Ro 64-6198 (0.3, 1.0, and 3.0 mg/kg i.p.) or naloxone (0.1, 1.0, and 10.0 mg/kg s.c.) were injected only once just before the postconditioning test. Animals in the control group received i.c.v. injections of artificial cerebrospinal fluid (2 µl) or i.p./s.c. injection of saline, respectively.
Influence of Nociceptin/Ro 64-6198/Naloxone on the Reinstatement of Ethanol-Induced Place Preference by a Priming Injection of Ethanol Solution. The acquisition of ethanol-induced (0.8-g/kg ethanol dose) place preference was performed as already described. After being tested for place preference, mice were subjected to 4 days of extinction trials (one trial per day) during which the mice were allowed to investigate both compartments for 20 min. During the last extinction trial the preference for the compartments was again recorded (last 10 min of the trial).
For experiments with nociceptin i.c.v. administration, the day after the last extinction trial the mice were operated and cannulae were implanted into the lateral ventricles. Three days after the operation (mice were left undisturbed) the reinstatement experiment was initiated. Mice were treated i.g. with either a 0.4-g/kg ethanol dose or with water. Five minutes after ethanol/water administration the mice were treated with nociceptin (5 nmol/2 µl i.c.v.) or CSF (2 µl i.c.v.) and allowed to explore the shuttle boxes. The time spent in the white compartment and the number of crossings between compartments were recorded as described above. The experiments with Ro 64-6198/naloxone administration were run similarly to the nociceptin study, e.g., 3 days after the last extinction trial. In the reinstatement experiment, separate groups of mice received, 5 min after being treated i.g. with either ethanol (0.4 g/kg) or with water, Ro 64-6198 (0.3 mg/kg i.p.), naloxone (1.0 mg/kg s.c.), or saline (i.p.) and were then allowed to explore the shuttle boxes. The time spent in the ethanol-associated compartment and the number of crossings between compartments were recorded as described above.Statistics
Data for the place conditioning effect (shift of the time spent on the ethanol-paired side) as well as the numbers of crossings between compartments during the 10-min test were analyzed by one- or two-way ANOVA followed by post hoc Newman-Keuls test when appropriate.
Effects of Ro 64-6198 on Locomotor Activity
Mice were individually tested in a dimly lit sound-controlled area ventilated by fans. They were removed from their home cages and placed in the middle of an activity monitor [standard transparent A3 (42 × 26 × 20 cm) Macrolon cage B&K Universal, AB, Sweden with 50 ml of wood shavings on the floor] and the data-collecting system was immediately activated. In experiments with nonhabituated animals, mice were treated with the drug just before placement in the activity box and different parameters of motor activity were recorded during 6 × 10-min intervals.
Motor activity was measured in eight animals simultaneously by means of
a multicage red and infrared-sensitive motion detection system
(Ögren et al., 1986
). The system is fully computerized and uses
beams of red and infrared lights in combination with vertical (infrared
light sensitive photocells in the walls of the apparatus) and
horizontal (red light-sensitive photocells in the floor of the
apparatus) arrays. The distance between photocells is 4 cm. Rearing was
measured by counting the number of times an animal stands on its hind
legs and interferes with any of the six invisible infrared beams
passing horizontally through the cages. The height of these photocells
was adapted to the size of the animal. Motility was measured as all
movements of a distance of 4 cm or more detected by 48 vertical
photocells, and represents a measurement of general activity.
Locomotion was measured by counting the number of times an animal had
covered eight horizontal photocells and moved from one side of the test
cage to the other side (a distance of at least 32 cm).
Effects of Subchronic Treatment with Ro 64-6198 on the Locomotor Inhibitory Effect of Ro 64-6198
Drug and experimentally naïve mice were treated twice a
day (10:00 AM and 6:00 PM) i.p. for 4 days with either saline or 1 mg/kg Ro 64-6198. On day 5, mice were randomly divided into three
treatment groups (n = 8):
| 1. | Subchronic treatment with saline + acute treatment with Ro 64-6198 (1 mg/kg). |
| 2. | Subchronic treatment with Ro 64-6198 + acute treatment with Ro 64-6198 (1 mg/kg). |
| 3. | Subchronic treatment with saline + acute treatment with saline. Immediately after treatment mice were placed into the "activity" boxes and their rearing, motility, and locomotion were recorded for 6 × 10-min periods. |
Dose-dependent effects of Ro 64-6198 on rearing, motility, and locomotion in mice were analyzed by ANOVA for repeated measures, the factors being treatment (drug doses and saline) and time (6 × 10-min recording). This was followed by a post hoc Newman-Keuls test for every time period recorded. The whole study was designed as a between subjects (independent groups) experiment (i.e., each animal was used only once).
| |
Results |
|---|
|
|
|---|
Dose-Dependent Effects of Ethanol in the CPP Paradigm
Measurement of the natural preference in the preconditioning test indicated that the mice displayed no preference for the particular compartment. One-way ANOVA revealed no significant differences between the experimental groups either in time spent in the white compartment or in the number of crossings between the compartments during the 10-min experiment. The mean number of crossings was about 17 to 25 in 10 min.
In animals with water conditioning (i.g. administration before placement in both compartments), a slight tendency for an increase in the time spent in the white compartment was found. No changes in the exploratory activity (number of crossings) were found after conditioning with water in both compartments.
Ethanol produced a significant place conditioning effect in NMRI mice
(Fig. 2). ANOVA revealed a significant
effect with respect to the shift of time spent in the ethanol-paired
compartment [F(3,20) = 6.5, p < 0.01]. Post hoc test revealed that the 0.8-g/kg ethanol group differed
significantly from the water group (p < 0.01) and the
mean increase in time spent in ethanol paired compartment was 95.3 s.
|
Ethanol-Induced CPP in Nociceptin Knockout (KO) Mice
Nociceptin KO male mice and their wild-type (WT) controls were
tested for the acquisition of ethanol-induced conditioned place preference comparing 0 (water), 0.4-, 0.8-, and 1.6-g/kg ethanol doses
(Fig. 3). Two-way ANOVA of the shift of
time spent in the ethanol-paired compartment revealed a significant
ethanol dose-related effect [F(3,35) = 8.2, p < 0.01] but no genotype effect
[F(1,35) = 3.0, p = 0.08] and no
genotype × dose interaction [F(3,35) = 0.3, p = 0.8]. In general, no genotype differences were
found but the nociceptin KO mice tended to show a stronger response to
ethanol (Fig. 3A). No significant genotype differences were found with
respect to the number of crossings between white and black compartments
(20-25 crossings in 10-min experiment) in post-test (Fig. 3C).
However, KO mice exhibited higher exploratory activity in the pretest
(Fig. 3B), which was indicated by a significantly higher number of
crossings between compartments [genotype effect F(1,35) = 5.2, p < 0.05]. Thus, it
was concluded that KO mice in comparison with WT mice displayed higher
exploratory activity in the novel environment and tended to show a
higher sensitivity to the conditioning effects of ethanol.
|
Effects of Nociceptin/Ro 64-6198 on the acquisition of ethanol-induced CPP
Nociceptin (5 nmol/2 µl/mouse) administration blocked (Fig.
4A) the acquisition of ethanol-induced
(0.8 g/kg) conditioned place preference [F(3,35) = 6.7, p < 0.01]. The post hoc test revealed a
significant (p < 0.01) reduction in the shift of time spent in the ethanol-paired compartment in the group pretreated with
nociceptin before ethanol administration. However, the groups treated
with CSF and nociceptin and received conditioning with water in both
compartments, did not differ. No significant reduction of the number of
crossing in groups treated with nociceptin during the post-test was
found.
|
Administration of Ro 64-6198 (0.1, 0.3, and 1.0 mg/kg i.p.)
reduced ethanol-induced conditioned place preference [Fig. 4B; F(3,28) = 33.5, p < 0.01] with a
significant effect even at the lowest dose tested (0.1 mg/kg,
p < 0.01 compared with the vehicle-treated group). It
is interesting that the combined administration of ethanol and Ro
64-6198 at the 0.3-mg/kg dose produced a significant aversion for the
compartment associated with the combination (
87.1 ± 9.7 s). There was a significant reduction in the number of crossings between the compartments in the group that received Ro 64-6198 at the
dose of 0.3 mg/kg (p < 0.05) but not at the 1.0-mg/kg
dose. In experiments with water conditioning, similar to nociceptin, Ro
64-6198 produced neither place preference nor place aversion, and there
were no differences between groups in the shift of time spent in the
compartment associated with drug treatment [F(3,28) = 0.11, p = 0.9].
Effects of Naloxone on the Acquisition of Ethanol-Induced CPP
Administration of naloxone (0.1, 1.0, and 10.0 mg/kg s.c.) reduced
ethanol-induced conditioned place preference (Fig. 4C) in a
dose-related way [F(3,20) = 9.8, p < 0.01]. However, a significant effect was found only at the highest
dose tested (10 mg/kg, p < 0.01, compared with the
saline-treated group). It is important to note that mice treated with
the naloxone (10 mg/kg) displayed reduced spontaneous locomotor
(significant reduction of the number of crossings, p < 0.01) activity, high level of grooming, and generalized reaction to
external stimuli with jumping and screaming. All this indicates that
naloxone at the 10-mg/kg dose causes nonspecific effects probably
unrelated to opioid systems. Importantly, the combined administration
of naloxone (10 mg/kg) and ethanol produced a significant aversion for
the compartment associated with the combination (
41.5 ± 19.7 s). In experiments with water conditioning, naloxone at the
0.1-mg/kg dose produced neither place preference nor place aversion.
However, the higher doses of naloxone (1.0 and 10 mg/kg) produced place
aversion (
12.2 ± 8.5 and
40.5 ± 21.3 s,
respectively) and a significant reduction of motor activity as shown
previously with the 10-mg/kg dose.
Effects of Nociceptin/Ro 64-6198 on the Expression of Ethanol-Induced CPP
In this set of experiments mice received a single administration
of nociceptin or Ro 64-6198 just before the postconditioning test (Fig.
5). In the experiments with nociceptin
administration (Fig. 5A) ANOVA revealed a significant group effect with
respect to the shift of time in the ethanol-paired compartment
[F(3,32) = 9.2, p < 0.01] and the
number of crossings in the postconditioning test
[F(3,32) = 10,4, p < 0.01].
Nociceptin administration blocked the expression of the ethanol-induced
CPP and reverted it to a place aversion (mean shift of time
54.3 ± 22.1, n = 9). In contrast, administration of
nociceptin to the animals, which received conditioning with water,
failed to produce place aversion (mean shift of time 34.0 ± 22.2, n = 8). Nociceptin treatment also significantly reduced the number of crossings between compartments (p < 0.01) in both groups (e.g., water-conditioning group and
ethanol-conditioning group).
|
Ro 64-6198 (0.1, 0.3, and 1.0 mg/kg i.p.) also blocked the expression
of ethanol-induced CPP (Fig. 5B) in a dose-related way [dose effect:
F(3,18) = 16.4, p < 0.01] and
reversed it to a clearcut place aversion at the dose of 1 mg/kg (mean
shift of time
51.7 ± 13.8, n = 8).
Interestingly, the same dose of Ro 64-6198 failed to produce place
aversion in the group conditioned with water (mean shift of time
15.3 ± 6.1, n = 8). Moreover, no significant differences between groups were observed [dose effect:
F(3,12) = 0.48, p = 0.6]. Treatment
with Ro 64-6198 (1 mg/kg) produced a significant reduction in the
number of crossings between compartments in the postconditioning test.
Effects of Naloxone on the Expression of Ethanol-Induced CPP
Treatment with naloxone (0.1, 1.0, and 10.0 mg/kg s.c.; Fig. 5C)
blocked the expression of ethanol-induced CPP in a dose-related way
[dose effect: F(3,20) = 12.2, p < 0.01] and reversed it to a clear-cut place aversion at the dose of 10 mg/kg (mean shift of time
52.8 ± 22.7, n = 8).
As in the acquisition experiments mice treated with the 10-mg/kg dose
of naloxone displayed behavioral inhibition and a significant reduction
of the number of crossings between compartments in post-test.
Administration of the opioid antagonist to the groups, which had
received conditioning with water, failed to produce significant place
aversion, although some tendency for the avoidance of the white
compartment was observed in mice treated with 10 mg/kg naloxone
regardless of the starting compartment in conditioning trials. No
significant differences between groups were observed [dose effect:
F(3,20) = 0.72, p = 0.6] in mice with
water conditioning.
Effect of Nociceptin, Ro 64-6198 and Naloxone on the Ethanol-Induced Reinstatement of CPP after Extinction
Figure 6 shows the results of the
experiments in which animals first acquired CPP and then were given
four daily extinction trials, and then received a single priming i.g.
administration of ethanol (0.4 g/kg i.g.). The data were analyzed using
a two-way repeated measures ANOVA with water versus ethanol
conditioning as the first between group factor and drug treatment
(nociceptin, CSF, saline, Ro 64-6198, and naloxone) as the second
between group factor. Three data blocks (post-test 1, post-test 2, and
post-test 3; Fig. 1) were used as the repeated measurement factor.
ANOVA revealed a significant conditioning effect
[F(1,80) = 63.9, p < 0.01] as well
as a significant interaction between conditioning and treatment
[F(4,80) = 2.7, p < 0.05] and
conditioning and time [F(2,160) = 37.4, p < 0.01]. Treatment effect and treatment × time interaction were also significant [F(4,80) = 6.0, p < 0.01 and F(8,160) = 6.5, p < 0.01, respectively].
|
It can be seen that time spent in the ethanol-paired chamber diminished after the extinction trials (Fig. 6) and it did not differ from the time spent in the water-paired chamber. Analysis of the shift of time in the three testing blocks (e.g., acquisition, extinction, and priming) revealed a significant shift of time spent in the ethanol-paired compartment [F(2,20) = 7.62, p < 0.01] in the control groups (i.c.v. CSF or i.p. saline), which received conditioning with ethanol solution (Fig. 6). This indicates that the time spent in the ethanol-paired compartment significantly increased after acquisition and after priming with ethanol (both p < 0.01, compared with the values obtained in pretest) but did not differ from pretest values after extinction trials. In contrast, animals that received only water administration (Fig. 6), displayed no significant shift of preference (compared with pretest values) after acquisition, extinction and priming with 0.4-g/kg ethanol dose. The priming injection of ethanol (0.4 g/kg i.g.), which by itself was ineffective to establish a significant CPP before the test, resulted in complete reinstatement of CPP in the group that had acquired a significant place preference reaction after conditioning with 0.8-g/kg ethanol dose. However, in animals primed with tap water (i.g.) there was no increase in time spent in the compartment previously associated with ethanol. Both nociceptin (i.c.v), Ro 64-6198 (0.3 mg/kg i.p.), and naloxone strongly inhibited the "priming" effect of the noncontingent administration of ethanol (p < 0.01 for nociceptin and Ro 64-6198 and p < 0.05 for naloxone, comparison between post-test 1 and post-test 3). In all groups treated with nociceptin and Ro 64-6198, a significant reduction (p < 0.05) of the number of crossings between compartments was observed (compared with the corresponding control groups treated with CSF/vehicle). Treatment with naloxone failed to influence the motor activity of mice.
Effects of Acute and Subchronic Treatment with Ro 64-6198 on Spontaneous Locomotor Activity in Mice
Effects of Acute Treatment with Ro 64-6198 (Fig.
7, left column).
In animals treated
with vehicle (n = 8), there was a gradual decrease of
motor activity over time and an almost complete elimination of rearing,
motility, and locomotion after 1 h of habituation to the activity
cages. Ro 64-6198 caused a significant influence on rearing
-F(3,39) = 3.8, p < 0.05] and
motility -F(3,39) = 4.7, p < 0.01]. A
significant time effect for rearing, motility, and locomotion
[F(5,195) = 61.7, p < 0.0001; 143.5, p < 0.001 and 83.6, p < 0.001, respectively] and a significant dose × time interaction for all
parameters [F(15,195) = 1.9, p < 0.05, 1.7, p < 0.05 and 2.1, p = 0.01, respectively] were also found. The post hoc Newman-Keuls test,
analyzed for each time point separately, revealed that there was a
significant (p < 0.01) lower level of rearing 20 and
30 min after treatment with Ro 64-6198 at the dose of 1 mg/kg (with respect to vehicle-treated group) motility and locomotion 20, 30, and
40 min after treatment with 1 mg/kg Ro 64-6198.
|
Effects of Subchronic Treatment with Ro 64-6198 on the Locomotor Inhibitory Effect of Ro 64-6198 (Fig. 7, right column). One-way ANOVA revealed significant group × time interaction for rearing, motility, and locomotion [F(10,105) = 2.4, p < 0.05; 3.7, p < 0.01; and 2.1, p < 0.05, respectively]. Subsequent post hoc analysis revealed that only the group that received subchronic treatment with saline and acute administration of Ro 64-6198 (sal-ro group) displayed significantly lower rearing, motility and locomotion at 10 to 40 min after treatment (p < 0.05, compared with group sal-sal). Subchronic treatment with Ro 64-6198 (1 mg/kg i.p.) did not cause a significant inhibition (compared with the control group sal-sal) of the locomotor activity.
| |
Discussion |
|---|
|
|
|---|
The present experiments have demonstrated that 1) intragastric administration of ethanol, paired with a distinct environment, can produce CPP in mice. The CPP can be extinguished by repeated exposure to the place conditioning environment in an ethanol-free state. 2) A priming administration of a low dose of ethanol, which in an alcohol-naive animal failed to induce significant place preference, reinstated the previously acquired and extinguished ethanol-induced CPP. 3) Nociceptin blocked the acquisition of ethanol-induced CPP in line with previous findings, a property shared by the synthetic nociceptin agonist Ro 64-6198. For the first time it was demonstrated that both nociceptin and the synthetic ORL1 agonist could block the expression and ethanol-primed reinstatement of CPP. 4) The nonselective opioid antagonist naloxone failed to block the acquisition of ethanol-induced CPP but inhibited the expression and ethanol-induced priming of the acquired CPP at the dose relevant for opioid receptor blockade.
There is a large body of experimental reports demonstrating
reliable ethanol-induced CPP in inbred and outbred mice (Cunningham et
al., 1991
; Crabbe et al., 1992
; Cunningham, 1995
; Risinger and Oakes,
1996
; Bormann and Cunningham, 1997
). In the present study, ethanol at
the dose of 0.8 g/kg produced maximal place conditioning effect in
outbred NMRI mice. This dose is somewhat lower than those previously
reported to induce of CPP in mice. Cunningham et al. (1992)
reported a
maximal conditioning effect with the doses 3 and 4 g/kg using DBA/2J
mice, whereas Risinger et al. (1996)
demonstrated significant CPP in
Swiss-Webster mice with ethanol doses 1 and 2 g/kg. The higher potency
of ethanol in our study compared with the previous reports might be
explained by the shorter conditioning trials used in the present study
(20 min) compared with 30 and 60 min in the cited study (Risinger and
Oakes, 1996
).
Comparing pronociceptin gene KO and WT mice we failed to observe
significant differences in the acquisition of ethanol-induced CPP. This
suggests that during basal conditions nociceptin systems probably play
a minor role in modulating the motivational effects of ethanol.
However, the increased reactivity of KO mice (as indicated by the
increased number of crossings between compartments in the pretest) was
noted, which supports previous observations about the higher reactivity
to novelty in nociceptin-deficient mice (Reinscheid et al., 1999
).
In animals, administration of the originally self-administered drug was
shown to be an effective cue for reinstatement of drug-taking behavior
(Stewart and Wise, 1992
). Here, it was found that repeated daily
testing in the absence of unconditioned stimuli lead to a reduction of
ethanol-induced CPP, supporting earlier observations obtained in mice
with cocaine-induced CPP (Mueller and Stewart, 2000
). However, after a
priming administration of a low dose of ethanol, the animals chose the
environment associated with the ethanol-related stimuli indicative of
the reinstatement of the extinguished place preference by the priming
dose of ethanol.
Examination of the motivational effects of nociceptin and the synthetic
nociceptin receptor agonist Ro 64-6198 revealed that both substances
are devoid of either reinforcing or aversive properties in mice,
supporting previous observations in rats (Devine et al., 1996a
;
Ciccocioppo et al., 1999
). However, when nociceptin and Ro 64-6198 were
tested versus the effect of ethanol in the place-conditioning paradigm,
they significantly reduced both the acquisition, expression, and
ethanol-induced reinstatement of CPP. Moreover, the combined administration of nociceptin/Ro 64-6198 and ethanol produced a clear-cut place aversion. The fact that nociceptin/Ro 64-6198 can
modulate the expression and reinstatement of the conditioned reinforcing effects of ethanol is of special importance. The
conditioned positive motivational responses are thought to underlie
"craving" in humans, and possibly contribute to relapse to drinking
in abstinent alcoholics (Stewart et al., 1984
). It could be argued that
the effects of nociceptin receptor ligands seem not to be due to
unspecific changes in behavior. Acute nociceptin is known to suppress
locomotor activity in rats (Devine et al., 1996b
) and mice (Reinscheid
et al., 1995
), although at low doses (lower than 1 nmol/mouse)
nociceptin is reported to increase locomotor activity, probably via an
"anxiolytic" action (Jenck et al., 1997
; Florin et al., 1996
). In
our experiments, we confirmed that both nociceptin (5 nmol/mouse) and
Ro 64-6198 (1 mg/kg) reduced locomotor activity after acute
administration. However, tolerance developed very quickly to this
effect and already after three injections we failed to observe a
significant reduction of locomotor activity as indicated by the number
of transitions between the compartments. This observation is in line
with the previous data obtained in rats (Devine et al., 1996b
;
Ciccocioppo et al., 1999
).
At present, the neurochemical mechanisms underlying the action of
nociceptin and Ro 64-6198 on the rewarding effects of ethanol and
reinstatement of ethanol-induced CPP are unknown. Nociceptin has been
shown to decrease basal (Murphy and Maidment, 1999
) and morphine-stimulated (Di Giannuario and Pieretti, 2000
) extracellular dopamine in the nucleus accumbens. This action of nociceptin is probably due to an activation of GABA-ergic interneurons, which exert
inhibitory control of mesolimbic dopaminergic neurons. It is also
possible that nociceptin can modulate the enkephalinergic fibers known
to project to the VTA and synapse with GABA neurons (Sesack and Pickel,
1995
). In addition, nociceptin has been shown to decrease glutamate
release in cortical slices (Nicol et al., 1996
).
Because the endogenous opioids seem to be essential for initiation and
maintenance of excessive alcohol consumption it was of interest to
include the opioid antagonist naloxone in the present study. Naloxone
failed to inhibit acquisition of ethanol-induced CPP at the doses that
are relevant to the opioid receptor blockade (0.1 and 1.0 mg/kg),
consistent with previously published data (Cunningham et al., 1995
).
However, at the highest dose tested (10 mg/kg) naloxone completely
blocked acquisition of CPP. The disturbances of the mice behavior with
the 10-mg/kg dose of naloxone are indicative of unspecific toxic
effects of naloxone, probably mediated via nonopioid mechanisms. At
doses 1 mg/kg and higher naloxone produced conditioned place aversion,
in line with previous observations (Cunningham et al., 1995
). In our
experiments, we unexpectedly found that naloxone could block the
expression of ethanol induced CPP at the doses 1 mg/kg and higher.
These doses of naloxone are known to nonselectively block all types of
opioid receptors (Pitts et al., 1996
) and this probably indicates that multiple opioid systems are involved in the acquisition and expression of ethanol-induced CPP. This observation contrasts with some previous reports (Cunningham et al., 1995
, 1998
; Bormann and Cunningham, 1997
)
but is in line with the findings of Middaugh and Bandy (2000)
. The
discrepancies in the results using naloxone might be explained by
differences in experimental approaches (biased versus unbiased procedure, different conditional cues, different duration of the conditioning trials as well as different strains of mice used). In our
experiments naloxone (1 mg/kg) also strongly inhibited the
reinstatement of ethanol-induced CPP primed by the low dose of ethanol
(0.4 g/kg). This is, to our knowledge, the first demonstration of the
"antirelapse" activity of an opioid antagonist in experiments with mice.
The results of these experiments can also be interpreted in terms
of a learning impairment or a retrieval deficit after treatment with
nociceptin agonists. In fact, nociceptin has been found to impair
hippocampal-dependent spatial learning (Higgins et al., 2002
). Thus, it
seems possible that nociceptin and its synthetic agonist can block the
formation of the learned association between the effects of ethanol and
environmental cues. In the reinstatement experiments, nociceptin
agonists may prevent memory retrieval mediated by a priming dose of
ethanol. Stimulation of nociceptin receptors may prevent the
reactivation of memory circuits by subthreshold stimuli (e.g., low
doses of ethanol or conditional environmental stimuli). Needless to
say, this hypothesis requires experimental confirmation.
In conclusion, the present results support the hypothesis that stimulation of nociceptin (ORL1) receptors reduces the reinforcing and motivational effects of ethanol in mice as well as reinstatement of preference for place induced by ethanol. This suggests that drugs targeted to this receptor may have therapeutic potential in the treatment of alcohol-seeking behavior and relapse.
| |
Acknowledgments |
|---|
We thank Drs. F. Jenck and J. Wichmann from F. Hoffmann-La Roche for the generous gifts of nociceptin knockout mice and the synthetic nociceptin agonist Ro 64-6198. Portions of these data were presented at the International Narcotic Research Club (INRC) 2001 Congress as a poster report (Helsinki, July 2001).
| |
Footnotes |
|---|
Accepted for publication September 23, 2002.
Received for publication July 9, 2002.
This project received financial support from The Marcus and Amalia Wallenberg Foundation, the Swedish Medical Research Council (project K2001-04X-11588-06A) and Karolinska Institutet.
DOI: 10.1124/jpet.102.041350
Address correspondence to: Professor Sven Ove Ogren, Department of Neuroscience, Karolinska Institutet, SE-171 77 Stockholm, Sweden. E-mail: sven.ove.ogren{at}neuro.ki.se
| |
Abbreviations |
|---|
CPP, conditioned place preference; ORL1, opioid receptor-like receptor 1; Ro 64-6198, (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one hydrochloride; OFQ, orphanin FQ; CSF, cerebrospinal fluid; i.g., intragastric; ANOVA, analysis of variance; KO, knockout; WT, wild-type.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
W. Xia, N.-N. Chu, J. Liang, Y.-J. Li, R. Zhang, J.-S. Han, and C.-L. Cui Electroacupuncture of 2 Hz has a Rewarding Effect: Evidence from a Conditioned Place Preference Study in Rats Evid. Based Complement. Altern. Med., June 19, 2008; (2008) nen043v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. V. Khroyan, N. T. Zaveri, W. E. Polgar, J. Orduna, C. Olsen, F. Jiang, and L. Toll SR 16435 [1-(1-(Bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a Novel Mixed Nociceptin/Orphanin FQ/{micro}-Opioid Receptor Partial Agonist: Analgesic and Rewarding Properties in Mice J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 934 - 943. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||